SymBio Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

SymBio Pharmaceuticals possède un total de capitaux propres de ¥5.2B et une dette totale de ¥0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont ¥6.1B et de ¥910.0M.

Informations clés

Ratio d'endettement

JP¥0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	JP¥5.13b
Fonds propres	JP¥5.16b
Total du passif	JP¥910.00m
Total des actifs	JP¥6.07b

Mises à jour récentes de la santé financière

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4582 ( ¥6.0B ) dépassent ses passifs à court terme ( ¥906.0M ).

Passif à long terme: Les actifs à court terme de 4582 ( ¥6.0B ) dépassent ses passifs à long terme ( ¥4.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4582 est sans dette.

Réduire la dette: 4582 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 4582 dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 4582 dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de croître à un taux historique de 34.4 % chaque année

SymBio Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Recent updates

Third quarter 2024 earnings released: JP¥28.45 loss per share (vs JP¥17.83 loss in 3Q 2023)

SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings released: JP¥16.75 loss per share (vs JP¥2.09 loss in 2Q 2023)

SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

New major risk - Share price stability

First quarter 2024 earnings released: JP¥18.02 loss per share (vs JP¥0.10 profit in 1Q 2023)

Full year 2023 earnings released: JP¥49.17 loss per share (vs JP¥30.20 profit in FY 2022)

SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLC

Full year 2023 earnings released

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 26%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023

Third quarter 2022 earnings released: EPS: JP¥11.32 (vs JP¥13.83 in 3Q 2021)

Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022

SymBio Pharmaceuticals Limited to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: JP¥24.36 (vs JP¥0.11 in 2Q 2021)

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

SymBio Pharmaceuticals Limited to Report Q2, 2022 Results on Aug 04, 2022

SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.

Investor sentiment improved over the past week

SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.

First quarter 2022 earnings released: EPS: JP¥4.25 (vs JP¥5.47 loss in 1Q 2021)

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Less than half of directors are independent

SymBio Pharmaceuticals Limited to Report Q1, 2022 Results on May 11, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS JP¥13.79 (vs JP¥23.01 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥0.10 (vs JP¥27.30 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

SymBio Pharmaceuticals Limited to Report Q1, 2021 Results on May 13, 2021

New 90-day high: JP¥1,380

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

New 90-day high: JP¥895

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

New 90-day low: JP¥337

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Third quarter 2020 earnings released: JP¥23.01 loss per share

New 90-day low: JP¥379

Symbio Pharmaceuticals Limited Receives Approval of TREAKISYM Ready-To-Dilute ('Rtd') Formulation, with Launch Expected in January 2021

New 90-day low - JP¥409

Earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines